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ABSTRACT 
Introduction:Markers of low-grade peripheral inflammation have been reported 
amongst people with epilepsy. The mechanisms underlying this phenomenon 
areunknown. Weattempted to characterize peripheral immune cells and their 
activation status in people with temporal lobe epilepsy (TLE)and healthy controls. 
Methods and Results:Twenty people with TLE and 19 controls were recruited, 
and peripheral blood lymphocyte and monocyte subsets evaluated ex vivoby multi-
color flow cytometry. People with TLE had higher expression of HLA-DR, CD69, 
CTLA-4, CD25, IL-23R, IFN-γ, TNF and IL-17 in CD4+ lymphocytes thancontrols. 
Granzyme A, CTLA-4, IL-23R and IL-17 expression wasalso elevated in CD8+ T 
cells frompeople with TLE. Frequency of HLA-DR in CD19+ B cells and regulatory 
T cells CD4+CD25+Foxp3+ producing IL-10 was higher in TLE when 
comparedwithcontrols. Anegative correlation between CD4+expressing co-
stimulatory molecules (CD69,CD25 and CTLA-4) with age at onset of seizures was 
found. The frequency of CD4+CD25+Foxp3+cells wasalso positivelycorrelated 
withage at onset of seizures. Conclusion:Immune cells of people withTLE show 
an activation profile, mainlyin effector T cells, in line with the low-grade peripheral 
inflammation. 
 
 
 
Key words:  Human temporal lobe 
epilepsy;Immunophenotyping;Lymphocytes;Cell activation;Cytokines. 
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INTRODUCTION 
Epilepsy is a major public health problem affecting around 1% of the 
population worldwide. Temporal lobe epilepsy (TLE) is the most common epileptic 
syndrome in adults,and is frequently associated with difficult control seizures. Its 
etiopathogenesis is complex, involving both genetic and environmental factors. 
Taking into account their role in plastic or structural changes in several 
organs,experimental studies have focused on the involvement of inflammatory 
mechanisms in epilepsy[1-3].  
Inflammation has generally been regarded as harmful to the brain as local 
(microglia) and infiltrating immune cells (CD4+ and CD8+ T cells), as well as pro-
inflammatory cytokines,such as interleukin (IL)-1β, tumor necrosis factor (TNF), 
and IL-6, mayexacerbate neuronal damage in epilepsy[2, 4]. Conversely,there is 
also evidence supporting a protective role for innate and adaptive immune cells as 
they cancontribute to seizure-suppression in animal models of TLE[5, 6].Whatever 
its effect or involvement, a growing body of evidence has supported a role for 
inflammatory mechanisms in epilepsy. This is mainly supported by the finding of 
high levels of pro-inflammatory cytokines,such as IL-1β, IL-6 and TNF,inthe 
cerebrospinal fluid(CSF) or bloodof people with epilepsy, notably TLE[7][8]. The 
meaning and/or the triggers of this low-grade inflammation in epilepsy is unknown. 
Only a few studies havecharacterizedthe peripheral immune cells in TLE[6, 9-14]. 
For instance, one study reportedelevated frequencyof monocytes and NK cells in 
people with refractory epilepsy to antiepileptic drugs (AEDs)[15]. 
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As previous studiesreported increased levels of circulating pro-inflammatory 
cytokines and/or mediators, suggesting a persistent peripheral low-grade 
inflammation in TLE, we hypothesized that cells of people with epilepsy would 
display an activated profile when compared with controls. To test this hypothesis, 
we evaluated the activation status and the production of cytokines byperipheral 
immune cells. 
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Methods 
Subjects:This study enrolled 20 people with TLE and 19 controlsrecruited from a 
tertiary referral center. The inclusion criteria for TLE were: diagnosis of TLE 
according to the ILAE criteria, age of more than 18 years, capacity to provide 
written informed consent, and seizure-free for at least 72 hoursreportedby the 
people with TLE and/ortheir companion. This period was chosenas previous 
studies showed that circulatingcytokines returned to basal levels at least 24 hours 
afterseizures[15, 16]. All patients had temporal mesial sclerosis on magnetic 
resonance imaging (MRI). Control group was recruited in Belo Horizonte, 
according to the following criteria: age more than 18 years and lack of any 
psychiatric disorder, any severe medical condition or neurological diseases 
including epilepsy. For both groups, the exclusion criteria were history of previous 
neurosurgery, use of anti-inflammatory and antibiotic drugs in the last two weeks, 
or cognitive impairment according to the Mini Mental State Examination and had 
other medical or neurologic diseases other than epilepsy.Sociodemographic (age, 
gender, ethnicity, marital status, occupational status and educational level) and 
clinical data (weight and height, age of onset, duration of epilepsy, seizure type, 
seizure frequency, medication use, AED regimen, MRI and EEG findings) were 
also collected for both groups. This study was approved by local ethics research 
committee under the protocol number 607.264-0.   
 
Peripheral blood mononuclear cell isolation and cell surface staining:Blood was 
collectedafter clinical interview and immediately processed.Whole blood cells were 
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obtained from K3-EDTA venous vacuum tubes.Erythrocytes were lysedusing ACK 
lysing solution (0.15 M NH4Cl, 1mM KHCO3 and 0.1mM Na2EDTA) and washed twice 
with cold phosphate buffer saline (PBS)(1200 rpm, 4º, 10 minutes). After erythrocyte 
lysis, white blood cell (WBC) were stained with a combination of fluorescein 
isothiocyanate (FITC), phycoerythrin (PE), cy5.5-chrome (Cy)-labeled or PerCP 5.5, 
allophycocyanin (APC), cy7- allophycocyanin (APC) and cy7-phycoerythrin (PE-
Cy7) antibodies directed against the surface molecules anti-CD3,anti-CD4, anti-CD8, 
anti-CD25,anti-CTLA-4, anti-CD69, anti-IL23R, anti-CD56, anti-CD19, anti-HLA-DR, 
anti-CD14, anti-CD16 and anti-CD86 (eBioscience, San Diego, CA, 
USA;BDPharMingen, San Diego, CA, USA and Invitrogen/Molecular Probes, 
Camarillo, CA, USA) for 20 minutes at 4ºC and data acquired using a FACSCantoII 
(Becton & Dickinson, San Jose, CA, USA). 
Intracellular cytokines and FoxP3 staining: White blood cells were analyzed for 
their surface profile and intracellular cytokine expression pattern. Briefly, cellswere 
fixed with phosphate buffer saline (PBS) and formaldehyde (2%) (Sigma-Aldrich, 
St. Louis, MO, USA) for 20 minutes.Fixed cells were permeabilized using saponin 
0,5% (Sigma-Aldrich) and stained using monoclonal antibodies for granzime-A, 
FoxP3, CTLA-4, TNF, IFN-γ, IL-17A and IL-10(Invitrogen/Molecular Probes and 
BDPharmingen) conjugated with phycoerythrin (PE) or allophycocyanin (APC). PE 
and APC-labeled immunoglobulin control antibodies and a control of unstaining WBC 
were also included in all experiments. Preparations were acquiredinFACSCantoII 
(Becton & Dickinson, San Jose, CA, USA). A minimum of 50,000 gated events 
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inlymphocytepopulation was acquired for analysis due to the low frequency of 
positive events being analyzed.  
Flow cytometry data analysis:Natural killer, T and B lymphocytes were analyzed 
for their intracellular cytokine and costimulatory surface marker expression pattern 
and frequency using the FlowJo program (Tree Star, Ashland, OR, USA). Limits for 
the quadrant markers were always set based on negative populations and isotype 
controls. At least three different fluorochromes were combined for each analysis. 
Gating strategy is depicted in Figure 1. Aftergating specific cell subsets, histograms 
were generated for evaluating the frequency of cells expressing the given surface 
markers or cytokines.These cells were then analyzed for the expression (frequency 
and mean fluorescent intensity, MFI) of a given marker using histograms with 
control markers based on negative isotype controls. 
 
Statistical analysis: Numerical variables were expressed as medianor mean with 
standard deviation. The frequency of cells wascompared using the nonparametric 
Mann-Whitney Utest. Correlation between the frequency of immune cells and 
clinical parameters was performed with the Spearman’scorrelation test. Statistical 
analysis was performed using the SPSS 17.0 package (SPSS Inc., Chicago, IL, 
USA). All tests were two-sided with a significance level of p < 0.05. 
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RESULTS 
Twenty people (12 men), aged 19 to 55 years (mean age ± SD,39 ± 11) 
were enrolled. Mean age at onset of seizures was6.8 years. The mean frequency of 
seizures was 3.0 per month.For control, 19 people without epilepsy or any 
psychiatric disorder, aged 24 to 65 years (mean age ± SD, 39 ± 9.3) were enrolled. 
Clinical features of subjects are shown in Table 1. There was no difference 
between controls and people with TLE regarding sex, mean age,body mass index 
and educational level (Table 1). However, people with TLE presented different 
marital (p= 0.005) and employment status (p<0.001) when comparedwith controls 
(Table 1). 
 
T lymphocytes from people with TLEshowed high expression of co-
stimulatory molecules 
There were no differences between people with TLEand controlsregarding 
the percentage of T cells (CD4+ and CD8+), monocytes (CD14+), B lymphocytes 
and regulatory T cells (Treg). 
We next sought to investigate the expression of co-stimulatory moleculeson 
peripheral lymphocytes. As shown in Figure2,people with TLEshowedhigher 
expression of CD25 and HLA-DR on CD4+ T cellsas compared with controls 
(Figure 2A andB). The expression of CD69 and CTLA-4 on both CD4+ and CD8+ T 
cell subsets was also higher in people with TLE (Figure 2C and D).  
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Increased intracellular cytokine expression in T cells from people with TLE 
Increasedintracellular levels of IFN-γ, IL-6 and TNF in CD4+ T cells 
werefound in people with TLEcomparedwith controls(Figure 3).  The expression of 
IL-17A was also higher in CD4+ and CD8+ T cells from people with TLE compared 
with controls (Figure 4A). 
IL-23R is a receptor that plays a pivotal role inthe induction of Th17-specific 
cells.Our results showed higher expression of IL-23R on CD4+ and CD8+T cells 
frompeople with TLEcomparedwith controls (Figure4B).  
 
Treg cellsfrom people with TLEexpress high levels of IL-10 
Regulatory T cells (Treg) may inhibit effector Th1, Th2 and Th17 cells by 
secreting IL-10 and transforming growth factor (TGF)-β[17].  
The frequency of IL-10 producing CD8+ T lymphocytes waselevated in TLE 
compared with controls (Figure 5A). People with TLE and controls had similar 
frequency of Tregcells (Figure 5B),but IL-10was increased 3-fold in Tregcells from 
people with TLE (Figure 5B).  
 
Innate response and granzymeA production exacerbated in people with TLE 
The total number of NK cells waslower in people withTLE in comparison with 
controls (Figure 6A),but the number of NK cells producing granzyme A was higher 
in the former (Figure 6A). The same pattern was observed for cytotoxic T cells 
producing granzyme A (Figure 6A).HLA-DR expression, a marker for lymphocyte 
activation, was higher in B cells from people with TLE than controls (Figure 6B). 
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Monocyte subpopulations were evaluated through the expression of the co-
stimulatory molecules CD86 and the FcγRIII receptor activation markerCD16. 
Whilethe frequency of monocytes expressing CD86washigher (Figure 7A), the 
frequency of monocytes expressing CD16 was lower in people with TLEthan 
controls(Figure7B). These results suggesting activation of classical monocytes in 
TLE were confirmed by higherMFI for HLA-DR, IL-6, CD86 in monocytes from 
people with TLE comparedwith controls (Figure8A). Also, a high frequency of IL-6 
and TNF in monocytes was founded (Figure 8B). 
 
Inflammatory association with clinical findings 
To evaluate the clinical meaning of these findings, we correlatedthe 
frequency of leukocyte subpopulations with clinically meaningful 
parameters(i.e.age at onset of seizures, mean time since onset of seizures and 
mean frequency seizures/month). A negative correlation between CD4+cells 
expressing CD25, HLA-DR and CTLA-4 with themean time since onset of seizures 
was noticed (Table 2). There was positive correlation betweenTreg percentage and 
mean time since onset of seizures (Table 2).No othercorrelation between immune 
cells and clinical parameters emerged.   
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DISCUSSION 
We characterized peripheral immune cells from people with TLE by 
assessing a comprehensive panel of cell-surface markers and intracellular 
cytokines. People with TLE had increased frequency of activated T cells (CD25, 
CD69, CTLA-4 and HLA-DR) comparedwith controls. Previous studies have 
already shown increased number of T cells [6, 15, 18, 19], but none has addressed 
the activation state of peripheral immune cells. 
Costimulatory molecules are pivotal for cell activation, proliferation and 
differentiation,and for cytokine production. The findings of high expression of 
CTLA-4, CD25, and HLA-DR in T lymphocytes from people with TLE indicate that 
these lymphocytes are in a state of chronic activation. Moreover, as CD69 is an 
earlyactivation marker,its increase in TLE indicates that thesepeople present a 
continuousand/or persistent immune activation. 
People with TLE also exhibited activation of innate immunity cells. 
Monocytes from people with TLE displayed a classical phenotype (CD14+CD16-), 
andincreased expression of CD86, HLA-DR, IL-6 and TNF, further indicating a pro-
inflammatory state. This finding in the periphery may be in line with the report of 
infiltration of monocytes/macrophages in areas of neuronal loss in humansamples 
of hippocampal sclerosis and experimental models of TLE [5, 23]. 
CD8+ and NK cells producing granzyme A were also increased in TLE 
compared with controls. Granzyme A is a serine protease involved in several 
immune functions, including cell death by non-apoptotic pathways[21, 24], and 
mediation of inflammatory cytokine release [25-27]. Granzyme A produced by 
CD8+ and NK cells could be involved in cytokine production and apoptotic 
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response in epilepsy. Interestingly, in Rasmussen encephalitis, granzyme B and 
TNF were increased in the CSF [19].  
When assessing intracellular cytokine production, we found increased 
expression of IL-6, IFN-γ, TNF and IL-17A in lymphocytes and monocytes. This 
finding is in line with previous studies reporting elevated cytokine levels in 
serum/plasma and CSF in the interictal period, but especially after seizures, in TLE 
and other epileptic syndromes [9, 15, 16, 18, 28, 29]. The mechanisms underlying 
this low-grade inflammation, i.e. the elevated circulating levels of pro-inflammatory 
cytokines, in TLE remain unclear. For some, active epilepsy is accompanied by a 
chronically up-regulated stress response which peaks in the postictal period, 
leading to persistent elevated levels of pro-inflammatory cytokines [7, 9, 16]. It is 
tempting to hypothesize that brain-derived damage-associated molecular 
pattern (DAMPs) could be responsible for persistent immune activation and related 
low-grade inflammation. DAMPs generated in the brain after seizures would induce 
a cascade of events leading to local and systemic inflammation (Figure 9). Indeed 
experimental studies have demonstrated that there is continuous recruitment of 
peripheral cells into the brain following seizures, with a parallel between the 
activation of immune cells in the CNS and in the periphery [3, 19-22]. 
We showed that IL-17A production is also increased in CD4+ and CD8+ T 
cells in people with TLE. IL-17A is implicated in the development of autoimmune 
diseases in the central nervous systems such as multiple sclerosis, andwas 
correlated with the severity of epilepsy [8]. Epidemiological studies showed that 
epilepsy is associated with autoimmune diseases [30, 31]. IL-23R is a receptor 
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involved in Th17 response skewing, being expressed on the surface of lymphoid 
cells, such as αβ and γδ T cells, innate lymphoid cells and myeloid-derived cells 
[32, 33]. Accordingly, we also found increased expression of IL-23R in T cells in 
TLE. 
People with TLEpresented increased IL-10 expression in Tregcells and 
CD8+ T cells. Tregcells inhibit both Th1 and Th2 effector cells, and also Th17-
mediated inflammation and autoimmunity. Their inhibitory mechanisms include 
engagement of cell-surface inhibitory receptors and production of soluble 
molecules. Treg cells cansecrete IL-10 and transforming growth factor (TGF)-β that 
inhibit pro-inflammatory responses. It is possible that Treg cells became active, 
producing more IL-10, in order to counterbalance the continuous pro-inflammatory 
response observed in TLE. 
Treg cells are central for the maintenance of peripheral immune tolerance, 
but theirrole in the central nervous systemis unclear. Besides secretion of IL-10, 
they can exert their immune suppressive function through cell contact-dependent 
mechanisms using inhibitory co-receptors such as CTLA-4 [41]. The correlation 
between the mean time since onset of seizures and the number of Tregis 
intriguing, and might reflectthe need of persistent compensatory mechanisms to 
counterbalance continuous pro-inflammatory stimuli. 
Our study has several limitations. The sample size is relatively small. The 
cross-sectional design of the study prevents definite causal assumption. All people 
with TLE were medicated, and AEDscould influence immune parameters. Most of 
these drug-related effects were anti-inflammatory or immunosuppressive,and 
people with TLE exhibited an enhanced inflammatoryimmune profiledespite the 
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use of AEDs.For instance, there wasdecreasedsecretion of pro-inflammatory 
cytokines, especially IL-1β and TNF, in human PBMC cultivated 
withcarbamazepine, lamotrigine, oxcarbazepine, phenobarbital, topiramate, and 
valproate[39]. CD8+ T cells secreting perforin reduced degranulation after culture 
with valproate and levetiracetam[40]. Accordingly, we could expect at most a 
moderating effect of these drugs on the findings, but not their explanation. One 
limitation regarding AEDs was that control for drug intake was not carried out. The 
current findings do not necessarily apply for TLE with controlled seizures, and 
further studies are warranted to confirm these results.  
In conclusion, our study offers further evidence of increased activationof 
circulating immune cells of those with TLE, supporting the consistently reported 
low-grade inflammation in epilepsy. 
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Table 1: Demographic and clinical characteristics of the study sample 
 
 
Total (n=42) 
TLE  
(n=20) 
Controls 
(n=19) 
Sex   
Male 12 (60%) 11 (58 %) 
Female 8 (40%) 8 (42 %) 
Mean age, years (SD) 38.7 (11.3) 39.8 (9.3) 
Educational level, years of study (SD) 8.0 (3.8) 11.6 (7.5) 
Marital status   
Single 13 (65%) 4 (21.05%) 
Married 7 (35%) 13 (68.4%) 
Divorced 0 (0%) 2 (10.52%) 
Body Mass Index (kg/m 2) 
 
Employment status 
26.12 ± 5.14 25.43 ± 9.78 
Employed 5 (25%) 17 (89.47%) 
Unemployed 9 (45%) 1 (5.26%) 
Retired 6 (30%) 1 (5.26%) 
Seizure type   
Simple partial 6 (30%)  
Complex partial 20 (100%)  
Partial evolving to secondary generalized 6 (30%)  
MRI   
RMTS 6 (30%)  
LMTS 9 (45%)  
BMTS 3 (15%)  
WMTS 2 (10%)  
Age at onset of epilepsy (years) 6.8 (7.7)  
Mean time since onset of seizures, years (SD) 26.2 (11.3)  
Mean frequency, seizures/month (SD) 3.0 (4.8)  
Seizure free for the last 6 months 3 (15%)  
AEDs, n (%)   
Valproate 5 (25%)  
Carbamazepine 15 (75%)  
Oxcarbazepine 1 (5%)  
Phenytoin 1 (5%)  
Phenobarbital 1 (5%)  
Lamotrigine 9 (45%)  
Topiramate 7 (35%)  
Benzodiazepines 19 (95%)  
AEDs therapy regime, n (%)   
Monotherapy  0  
Dualtherapy  4 (20%)  
3 AEDs 14 (70%)  
4AEDs 2 (10%)  
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SD = Standard deviation; MRI = Magnetic Resonance Imaging; WMTS = Without MTS; RMTS = Right Mesial Temporal Sclerosis; 
LMTS = Left Mesial Temporal Sclerosis; BMTS = Bilateral MTS; AEDs = Antiepileptic Drugs. 
ax2 
b
 Fisher’s Exact test 
cMann–Whitney U test 
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Table 2:Ex vivo correlations between clinical aspects of seizure disorder and 
inflammatory characteristics and T regulatory cells from TLE  
Correlation Analysis* Spearman's rho p 
Mean time since onset of seizures (years) x CD4+CTLA4+ -0.465 0.045 
Mean time since onset of seizures (years) x CD4+HLA-DR+ -0.643 0.003 
Mean time since onset of seizures (years) x CD4+CD25+ -0.588 0.008 
Mean time since onset of seizures (years) x CD4+CD25+FOXP3+ 0.514 0.024 
*The correlation analysis was performed with an “n” of 19, using the Spearman correlation coefficient and results 
were considered significant with a p<0.05.  
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Figure Legends 
 
 
Figure 1. Representative flow cytometry graphs of CD8+ T cells expressing 
granzyme A from control individual (CT) (B) and participant with temporal lobe 
epilepsy (TLE) (C). Flow cytometry dot-plots demonstrate the region of total lymphocytes 
(A) and the data analyzed in CD8+ T cells (B and C) expressing granzyme A and 
histograms (D) in controls (black line) and TLE (red dashed line). 
 
Figure 2. CD25, HLA-DR, CD69 and CTLA-4 expression in T lymphocytes from 
temporal lobe epilepsy (TLE) and controls (CT) in ex vivo condition. Graphs show (A) 
CD25 and (B) HLA-DR expression on CD4+ T cells. Graphs show (C) CD69 and (D) 
CTLA-4 expression on CD4+ and CD8+ T lymphocytes. Significant differenceswere 
considered when p< 0.05 (Mann-Whitney U test). 
 
Figure 3. IFN-γ, IL-6 and TNF expression by T lymphocytes from people with TLE 
and controls (CT) in ex vivo condition. Graph (A) IFN-γ show expression of this cytokine 
in T cells (CD4+ and CD8+). Graph (B) IL-6 and TNF show expression of these cytokines in 
CD4+ T lymphocytes. Significant differences were considered when p< 0.05 (Mann-
Whitney U test). 
 
Figure 4. IL-17A and IL-23R expression by T lymphocytes from people with TLE and 
controls in ex vivo condition. Data were collected using flow cytometry and analyzed 
using Flowjo software. Graphs show (A) IL-17A and (B) IL-23R expression in T cells (CD4+ 
and CD8+). Significant differences were considered when p< 0.05 (Mann-Whitney U test). 
 
Figure 5. IL-10 expression by T lymphocytes and T regulatory cells from people with 
TLE and controls (CT) in ex vivo condition. (A) IL-10 expression in T cells (CD4+ and 
CD8+) and (B) IL-10 intracellular production by T regulatory cells (CD4+CD25highFoxp3+). 
Significant differences were considered when p< 0.05 (Mann-Whitney U test). 
 
Figure 6. Granzyme A expression by NK cells and CD8 T lymphocytes, and HLA-DR 
frequency in B cells from people with TLE and controls (CT) in ex vivo condition. (A) 
Granzyme A expression in CD56+ NK and CD8+ T cells and (B) HLA-DR frequency on 
CD19+ B cells. Significant differences were considered when p< 0.05 (Mann-Whitney U 
test). 
 
Figure 7. CD86 and CD16 expression by CD14+ monocytes from people with TLE and 
controls (CT) in ex vivo condition. Graph (A) shows CD86 expression on different 
CD14+ monocytes subtypes. Graph (B) shows CD16 expression in different CD14+ 
monocytes subtypes. Significant differences were considered when p< 0.05 (Mann-
Whitney U test). 
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Figure 8. CD86, HLA-DR, IL-6 and TNF expression by CD14+ monocytes from people 
with TLE and controls (CT) in ex vivo condition. Graph (A)shows HLA-DR, IL-6 and 
CD86 mean intensity fluorescence (MFI) in total monocytes.Graph (B) shows IL-6 and 
TNF expression in CD14+ monocytes. Significant differences were considered when p< 
0.05 (Mann-Whitney U test). 
 
Figure 9. Peripheral inflammation could perpetuate brain damage in temporal lobe 
epilepsy (TLE) people. People with TLEwith uncontrolled seizures may present 
continuous release of damage-associated molecular patterns (DAMPs) that activate 
microglia and astrocytes. These cells release mediator factors that induce changes in the 
blood brain-barrier (BBB), facilitatingthe infiltrationof peripheral immune cells. In the blood, 
innate and adaptive immune responses can also be activated. Accordingly, it is observed 
increased expressionof costimulatory surface markers and cytokines (IL-6 and TNF) by 
CD14+ monocytes, while NK and CD8+ cytotoxic cells produce moregranzyme A, a 
molecule capable of inducing cell death. There is also a high frequency of CD4+ and CD8+ 
T cells expressing costimulatory markers and pro-inflammatory cytokines. All 
theseimmune cells might increase and/or support peripheral low-grade inflammation and 
brain tissue damage with further DAMPs generation. To modulate this exacerbated 
immune response, there is an elevated number ofTreg cells producing IL-10 in TLE.  
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Highlights 
 
1 - Immune cells of temporal lobe epilepsy (TLE) people show an activation profile. 
2- Regulatory T cells produced significantly more IL-10 in people with TLE whereas 
number of Treg cells was comparable. 
3- Effectors T cells are involved in activation profile in TLE people. 
 
 
